Advertisement
Screener

ALTIMMUNE, INC. (ALT) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

1.1 / 5 stars · 19/86 Roast Me

ALTIMMUNE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

ALTIMMUNE, INC. (ALT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-06.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-03-06

  • ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2018-03-31 was 0.00%.
  • ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
  • ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
  • ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
  • ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2025-12-310.00%
10-K · filed 2026-03-06
2024-12-310.00%
10-K · filed 2026-03-06
2023-12-310.00%
10-K · filed 2025-02-27
2022-12-310.00%
10-K · filed 2024-03-27
2021-12-310.00%
10-K · filed 2023-02-28
2020-12-310.00%
10-K · filed 2022-03-15
2019-12-310.00%
10-K · filed 2021-02-25
2018-12-310.00%
10-K · filed 2020-03-27
2018-03-310.00%
10-Q · filed 2018-05-15
2017-12-310.00%
10-K · filed 2019-04-01
2016-12-310.00%
10-K · filed 2018-04-02
2015-12-310.00%
10-K · filed 2017-03-14
2014-12-310.00%
10-K · filed 2017-03-14
2013-12-310.00%
10-K · filed 2016-03-11
2012-12-310.00%
10-K · filed 2013-03-14
2011-12-310.00%
10-K · filed 2013-03-14
2010-12-310.00%
10-K · filed 2013-03-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Monopar Therapeutics (MNPR)United States$0.598B-34.82
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
CorMedix Inc. (CRMD)United States$0.605B3.25
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76
Neurogene Inc. (NGNE)$0.625B-4.46
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
Indaptus Therapeutics, Inc. (INDP)United States$0.537B